- Home
- AUST vs PASG Comparison
AUST vs PASG Comparison
Compare AUST & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | PASG |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 19.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUST | PASG |
|---|---|---|
| Price | $1.12 | $4.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 46.0K | ★ 90.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $3.29 |
| 52 Week High | $3.92 | $20.00 |
Technical Indicators
Market Signals| Indicator | AUST | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 41.77 |
| Support Level | $1.06 | $3.94 |
| Resistance Level | $1.42 | $6.01 |
| Average True Range (ATR) | 0.07 | 0.53 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 12.50 | 46.18 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.